Taysha Gene Therapies, Inc. (TSHA) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in CapitalUSD $1.19B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $769.00K; Retained Earnings (Accumulated Deficit)USD $-800.35M.
- 2026-03-31: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in CapitalUSD $964.67M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $985.00K; Retained Earnings (Accumulated Deficit)USD $-753.71M.
- 2025-12-31: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in CapitalUSD $958.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-192.00K; Retained Earnings (Accumulated Deficit)USD $-711.30M.
- 2025-09-30: Common Stock, Value, IssuedUSD $3.00K; Additional Paid in CapitalUSD $903.58M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.14M; Retained Earnings (Accumulated Deficit)USD $-683.45M.
Taysha Gene Therapies, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.00K | $1.19B | $769.00K | $-800.35M | $387.27M | 3 month · $5.81M 6 month · $11.36M | (m) | (m) |
| 2026-03-31 | $3.00K | $964.67M | $985.00K | $-753.71M | $211.94M | 3 month · $5.55M | (m) | (m) |
| 2025-12-31 | $3.00K | $958.43M | $-192.00K | $-711.30M | $246.94M | 12 month · $13.30M | 12 month · $1.64M | (m) |
| 2025-09-30 | $3.00K | $903.58M | $-1.14M | $-683.45M | $218.99M | 3 month · $3.29M 9 month · $9.77M | (m) | (m) |
| 2025-06-30 | $3.00K | $900.14M | $-699.00K | $-650.72M | $248.73M | 3 month · $3.19M 6 month · $6.48M | (m) | (m) |
| 2025-03-31 | $2.00K | $681.18M | $-2.29M | $-623.83M | $55.06M | 3 month · $3.29M | (m) | (m) |
| 2024-12-31 | $2.00K | $677.86M | $-4.03M | $-602.30M | $71.53M | 12 month · $13.10M | (m) | (m) |
| 2024-09-30 | $2.00K | $674.64M | $-2.33M | $-583.52M | $88.80M | 3 month · $3.36M 9 month · $9.89M | (m) | (m) |
| 2024-06-30 | $2.00K | $664.46M | $2.40M | $-558.00M | $108.87M | 3 month · $3.33M 6 month · $6.53M | (m) | (m) |
| 2024-03-31 | $2.00K | $591.17M | $-251.00K | $-537.07M | $53.85M | 3 month · $3.20M | (m) | (m) |
| 2023-12-31 | $2.00K | $587.94M | (m) | $-513.01M | $74.94M | 12 month · $7.91M | 12 month · $74.34M | (m) |
| 2023-09-30 | $2.00K | $511.63M | (m) | $-560.75M | $-49.11M | 3 month · $2.04M 9 month · $5.94M | (m) | (m) |
| 2023-06-30 | $1.00K | $406.55M | (m) | $-443.66M | $-37.11M | 3 month · $2.22M 6 month · $3.90M | (m) | (m) |
| 2023-03-31 | $1.00K | $404.11M | (m) | $-419.06M | $-14.95M | 3 month · $1.68M | (m) | (m) |
| 2022-12-31 | $1.00K | $402.39M | (m) | $-401.44M | $949.00K | 12 month · $18.27M | (m) | (m) |
| 2022-09-30 | $1.00K | $357.06M | (m) | $-345.94M | $10.70M | 3 month · $4.47M 9 month · $14.17M | (m) | (m) |
| 2022-06-30 | $1.00K | $352.34M | (m) | $-319.63M | $32.51M | 3 month · $4.25M 6 month · $9.70M | (m) | (m) |
| 2022-03-31 | (m) | $336.49M | (m) | $-285.76M | $50.74M | 3 month · $5.45M | (m) | (m) |
| 2021-12-31 | (m) | $331.03M | (m) | $-235.65M | $95.38M | 12 month · $18.60M | (m) | (m) |
| 2021-09-30 | (m) | $325.66M | (m) | $-185.26M | $140.39M | 3 month · $5.09M 9 month · $13.23M | (m) | (m) |
| 2021-06-30 | (m) | $320.57M | (m) | $-134.08M | $186.50M | 3 month · $4.55M 6 month · $8.14M | (m) | (m) |
| 2021-03-31 | (m) | $316.02M | (m) | $-93.15M | $222.87M | 3 month · $3.59M | (m) | (m) |
| 2020-12-31 | (m) | $312.43M | (m) | $-61.13M | $251.30M | 12 month · $3.35M | (m) | 12 month · $15.14M |
| 2020-09-30 | (m) | $310.45M | (m) | $-42.81M | $267.64M | 3 month · $1.34M 9 month · $1.34M | (m) | 3 month · $15.11M 9 month · $15.11M |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-26.79M | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-5.57M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $980.00K | (m) | $-1.11M | $-135.00K | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | $-31.00K | (m) | (m) | (m) |
| 2019-09-20 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |